We are live on ! Find out more
PRTK

Paratek Pharmaceuticals, Inc.

Delisted

PRTK was delisted on the 20th of September, 2023.

66 hedge funds and large institutions have $47M invested in Paratek Pharmaceuticals, Inc. in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 12 increasing their positions, 19 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 17

5% more funds holding

Funds holding: 6366 (+3)

20% less capital invested

Capital invested by funds: $59M → $47M (-$12M)

37% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 19

44% less call options, than puts

Call options by funds: $146K | Put options by funds: $260K

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
66
Holders Change
+3
Holders Change %
+4.76%
% of All Funds
1.04%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
21
Increased
12
Reduced
19
Closed
17
Calls
$146K
Puts
$260K
Net Calls
-$114K
Net Calls Change
-$252K
Name Holding Trade Value Shares
Change
Change in
Stake
Invesco
76
Invesco
Georgia
-$40.8K -16,051 Closed
AWA
77
Arete Wealth Advisors
Illinois
-$36K -14,050 Closed
SSA
78
Schonfeld Strategic Advisors
New York
-$35.3K -13,900 Closed
Qube Research & Technologies (QRT)
79
Qube Research & Technologies (QRT)
United Kingdom
-$30.6K -12,028 Closed
BBA
80
Baader Bank Aktiengesellschaft
Germany
-$22.9K -11,580 Closed
CCB
81
Cutter & Co Brokerage
Missouri
-$27.7K -10,900 Closed
Northwestern Mutual Wealth Management
82
Northwestern Mutual Wealth Management
Wisconsin
-$254 -100 Closed
Simplex Trading
83
Simplex Trading
Illinois
+$46 +22 New

PRTK Hedge Fund Activity: Q2 2023 in Review

66 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q2 2023, worth a combined $47M — down 20% from $59M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new PRTK positions and 17 closed out — a net gain of 4 holders — while 12 added to existing stakes and 19 trimmed.

The largest buyer was Newtyn Management, opening a new position worth an estimated $1.59M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $6.79M sold.

  • 66 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q2 2023, up from 63 in Q1 2023.
  • Funds reported $47M of Paratek Pharmaceuticals, Inc. stock for Q2 2023, down 20% quarter-over-quarter.
  • 21 funds opened new Paratek Pharmaceuticals, Inc. positions in Q2 2023 and 17 closed out, a net change of +4 holders.
  • The largest Paratek Pharmaceuticals, Inc. buyer in Q2 2023 was Newtyn Management, an estimated $1.59M added.
  • The largest Paratek Pharmaceuticals, Inc. seller in Q2 2023 was AIGH Capital Management, an estimated $6.79M sold.

Based on aggregated 13F filings for Q2 2023.